Cmed Group announce award from GlaxoSmithKline
Major new study in P.Vivax malaria in emerging markets
Horsham, UK - October 26 2010 - Cmed are delighted to announce the award from GlaxoSmithKline (Diseases of the Developing World Group) of a major new study in P.Vivax malaria in emerging markets.
The project requires the collection and management of clinical data from a number of remote sites across Asia and South America and is being performed in collaboration with Medicines for Malaria Venture.
Dr David Connelly, CEO of Cmed Group said,” It is very gratifying that the features of Timaeus, our next generation unified EDC/CDM system, which make it the ideal system for work in such challenging clinical locations, have been recognised by a company of the stature of GSK. The ability of Timaeus to collect and transmit electronic clinical data independent of a fixed line internet connection is unique, making it the ideal eClinical technology for this study across this geography.”
About Cmed Group Ltd
For pharmaceutical, biotech and research organizations that need to accelerate the right medicines to market, Cmed Group is an innovative clinical trials company that specializes in providing state-of-the-art technology products and diverse services. Unlike separate eClinical technology and contract research organization (CRO) vendors, Cmed Group takes a flexible and efficient approach in providing the right solution that meets our customers’ changing needs and expectations. As a result, Cmed Group expedites clinical trials operations to provide immediate real-world results for clinical trial sponsors through its companies: Cmed Clinical Services, a full-service CRO, and Cmed Technology, an eClinical technology provider. For further information visit www.cmedgroup.com
###
